VEGFR-1 Inhibitors Market Size, Share & Trends Analysis Report, By Drug Type (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, and Others), By Application (Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, and Other), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Region, Forecasts, 2024-2031
VEGFR-1 Inhibitors Market Size is predicted to grow at a 7.0% CAGR during the forecast period for 2024-2031.
VEGFR-1 inhibitors are essential in treating various cancers by targeting the vascular endothelial growth factor receptor-1, which is crucial for angiogenesis and tumor growth. The increasing prevalence of cancer and advancements in targeted therapies are expected to drive the adoption of VEGFR-1 inhibitors. Additionally, ongoing research, regulatory approvals, and rising healthcare expenditure are anticipated to propel market growth. However, high treatment costs and potential side effects could restrain market expansion.
The most common types of cancer include colon and rectum, leukemia, prostate, breast, lung, bronchus, melanoma, kidney and renal pelvis, and pancreatic cancer. These factors contribute to the market's growth. However, the side effects associated with these inhibitors could limit market expansion during the forecast period. Side effects of these inhibitors include hypertension, stroke or heart attack, reversible posterior leukoencephalopathy syndrome, impaired wound healing, and protein in the urine.
Competitive Landscape
Some of the Major Key Players in the VEGFR-1 Inhibitors Market are
- Eisai Co., Ltd.
- Merck & Co., Inc.
- Advenchen Laboratories, LLC
- Sino Biopharmaceutical Limited
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Exelixis, Inc.
- Ipsen S.A.
- Pfizer Inc.
- Hutchison China MediTech Limited (Hutchmed)
- Mirati Therapeutics, Inc.
- Eli Lilly and Company
- Clovis Oncology, Inc.
- Les Laboratoires Servier (Servier)
- Pharma Mar, S.A.
- F. Hoffmann-La Roche AG (Roche)
- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen)
- Teva Pharmaceutical Industries Ltd.
Market Segmentation:
The VEGFR-1 inhibitors market is segmented by drug type, application, and distribution channel. By drug type, the market includes monoclonal antibodies, tyrosine kinase inhibitors, and other drug types. By application, the market is divided into renal cell carcinoma, colorectal cancer, non-small cell lung cancer, and other applications. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.
Monoclonal Antibodies Are A Major Contributor In The VEGFR-1 Inhibitors Market.
The monoclonal antibodies segment is expected to hold a significant share of the global VEGFR-1 inhibitors market in 2021, attributed to their high specificity and effectiveness in targeting cancer cells while minimizing harm to normal cells. Increasing approvals and clinical trials of monoclonal antibodies are further boosting their market growth.
The Non-Small Cell Lung Cancer Segment Is Growing Rapidly.
The non-small cell lung cancer segment is projected to grow at a rapid rate due to the high prevalence of lung cancer and the increasing use of targeted therapies. The rising incidence of smoking-related cancers and advancements in lung cancer treatments are driving this segment's growth.
North America Leads The VEGFR-1 Inhibitors Market In Terms Of Revenue.
North America is expected to dominate the VEGFR-1 inhibitors market in terms of revenue, due to its well-established healthcare infrastructure, high cancer prevalence, and substantial R&D investments. Additionally, the presence of major pharmaceutical companies and favorable regulatory policies support market growth. The Asia-Pacific region is projected to experience rapid growth due to increasing healthcare awareness, improving healthcare facilities, and a growing patient population.
Recent Developments:
- In January 2022, Pfizer Inc. received FDA approval for a new VEGFR-1 inhibitor for the treatment of advanced renal cell carcinoma.
- In March 2023, Novartis AG announced positive results from a phase III clinical trial of its investigational VEGFR-1 inhibitor for the treatment of non-small cell lung cancer.
VEGFR-1 Inhibitors Market Report Scope
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 7.0% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Drug Type, By Application, By Distribution Channel and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Eisai Co., Ltd., Merck & Co., Inc., Advenchen Laboratories, LLC, Sino Biopharmaceutical Limited, Novartis AG, Takeda Pharmaceutical Company Limited, Exelixis, Inc., Ipsen S.A., Pfizer Inc., Hutchison China MediTech Limited (Hutchmed), Mirati Therapeutics, Inc., Eli Lilly and Company, Clovis Oncology, Inc., Les Laboratoires Servier (Servier), Pharma Mar, S.A., F. Hoffmann-La Roche AG (Roche), Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen), and Teva Pharmaceutical Industries Ltd. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of VEGFR-1 Inhibitors Market-
VEGFR-1 Inhibitors Market- By Drug Type:
- Monoclonal Antibodies
- Tyrosine Kinase Inhibitors
- Other Drug Types
VEGFR-1 Inhibitors Market- By Application:
- Renal Cell Carcinoma
- Colorectal Cancer
- Non-Small Cell Lung Cancer
- Other Applications
VEGFR-1 Inhibitors Market- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
VEGFR-1 Inhibitors Market- By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
VEGFR-1 Inhibitors Market Size is predicted to grow at a 7.0% CAGR during the forecast period for 2024-2031.
Eli Lilly and Company, Clovis Oncology, Inc., Les Laboratoires Servier (Servier), Pharma Mar, S.A., F. Hoffmann-La Roche AG (Roche), Shenzhen Chipscre